Skip Main Navigational Links to Main Body
About UsWhat's NewStructureServicesProductsUseful Links
Skip About Us to Structure
About Us Home
Mission Statement
Our Objective
Corporate Profile
Management Team
Skip Structure to Services
Press Release
Skip Services to Products
Biotechnology Incubation Centre
Biologics Unit
GMP Consultation Services
Traditional Chinese Medicine
Skip Pipeline to Newsroom
Biotechnology Incubation Centre
Biologics Unit
GMP Consultation Services
Traditional Chinese Medicine
Skip Newsroom to Investors
LifeArtTM Products
e-Shops
Skip Investors to Careers
Related C.U.H.K Unit
Regulatory Authorities
Local Information Sources
Skip Careers to Main Body
Enquiries Home
Biotechnology Unit
Incubation Centre
Traditional Chinese Medicine
 





Site Index

       
   
 

       
 
 
 
 
 
 
 
 
 

 

HONG KONG'S BIOTECH INSTITUTE TO OPEN

A NEW GMP MULTIPURPOSE PURIFICATION PILOT PLANT

 
To further enhance Hong Kong's strong position in biotechnology research and product development, the Hong Kong Institute of Biotechnology (HKIB), a wholly owned subsidiary of the Chinese University of Hong Kong, had designed and constructed a new biotechnology and plasma-derived therapeutics downstream pilot GMP facility which is funded by the Innovation and Technology Programme of The Innovation and Technology Fund of the Hong Kong SAR Government. The new Plant serves as a multipurpose protein purification platform for the production of clinical grade materials with built-in biopharmaceutical manufacturing systems in accordance with Hong Kong and China Good Manufacturing Practice (GMP) requirements.

"The new Plant is an important element in our goal to make Hong Kong the city of biotechnology," said Prof. Walter Ho, Managing Director of HKIB. "By continuing to support this critical industry, from initial research to manufacturing, we are ensuring that the industry continues to grow and develop."

The new Plant is designed to enhance HKIB's multifaceted relationships with industry, academic and government institutes. It also permits acceleration of basic and applied product research in partnership with industry such as the project sponsor, Advantek Biologics Limited, which will make use of the Plant to develop plasma-derived therapeutics using technologies licensed from Amersham Biosciences (a business unit of General Electric Company, NYSE: GE), New York Blood Center and Asahi Kasei Pharma Corporation (TSE: 3407). The targeted markets for these products include a wide spectrum of diseases such as primary immune deficiency, lupus, Hepatitis B and rabies. According to Dr. Bing Lou Wong, CEO of Advantek, it is the first step of a series of initiatives jointly undertaken in Hong Kong and China to help alleviate the severe shortage of the US$8 billion global plasma therapeutic market.

CUHK and The Board of Directors of HKIB are grateful that the Hong Kong SAR Government continues to support the vision of HKIB and expand its missions. HKIB will continue to make positive impacts on the industrial front for Hong Kong and new efforts to promote and attract biotechnology R&D and investments.

About HKIB

Hong Kong Institute of Biotechnology Ltd. (HKIB), a subsidiary of the Council of The Chinese University of Hong Kong, is a non-profit private company founded in 1989 with a donation from The Hong Kong Jockey Club Charities Trust. In 2003, The Chinese University Institute of Biotechnology (CUIB) has been formed as a parallel organization to reflect the direction relationship between the University and the Institute. Since the inception, HKIB has set itself up as an outward-looking, market-aligned downstream development organization and has been the leading force in promoting the development of the biotechnology- and Chinese Medicine-based industries within Hong Kong and in the Greater China Region. Its mission is to advance applied academic research and to provide the vital link between technology transfer and product commercialization.

About Advantek

Advantek Biologics Limited is engaged in the R&D, commercialization, manufacture, marketing and sale of plasma-derived therapeutics, and research and diagnostic reagents. Advantek is the first and only Hong Kong-based protein therapeutics manufacturer. To reflect a mission of bringing safe protein therapeutics to patients in need, particularly those living in developing countries, Advantek has adopted "Saving Lives Through Safe Biologics" as corporate motto.

The Hong Kong Institute of Biotechnology Limited.
2 Biotechnology Avenue, 12 Miles, Tai Po Road, Shatin, N.T., Hong Kong. Tel: (852) 26035111, Fax: (852) 26035012
Copyright 2005 © The Hong Kong Institute of Biotechnology Limited. All rights reserved.